LIDDS announced that Markus Thor has been appointed as Head of Business Development and will join the company in March 2019. The employment is a consequence of the enlarged project portfolio and the broad interest from the pharma industry for the NanoZolid technology. Markus Thor has a thorough experience in business development and out-licensing from companies like Biovitrum, Kancera and Medivir. Markus currently works as Senior Investment Advisor at Business Sweden and will start his new position at LIDDS in March 2019.